Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A, Marmé F, Ruiz A, Manikhas AG, Bottini A, Wolf M, Sinn HP, Mansouri K, Kennedy L, Bauknecht T. Schneeweiss A, et al. Among authors: bauknecht t. Ann Oncol. 2011 Mar;22(3):609-617. doi: 10.1093/annonc/mdq400. Epub 2010 Aug 23. Ann Oncol. 2011. PMID: 20732932 Free article. Clinical Trial.
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Schneeweiss A, et al. Among authors: bauknecht t. Clin Breast Cancer. 2007 Apr;7(7):555-8. doi: 10.3816/CBC.2007.n.011. Clin Breast Cancer. 2007. PMID: 17509164 Clinical Trial.
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Vergote IB, Chekerov R, Amant F, Harter P, Casado A, Emerich J, Bauknecht T, Mansouri K, Myrand SP, Nguyen TS, Shi P, Sehouli J. Vergote IB, et al. Among authors: bauknecht t. J Clin Oncol. 2013 Sep 1;31(25):3127-32. doi: 10.1200/JCO.2012.44.9116. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897968 Clinical Trial.
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G. Sehouli J, et al. Among authors: bauknecht t. Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7. Cancer Chemother Pharmacol. 2010. PMID: 20054549 Clinical Trial.
Phase II study of gemcitabine in ovarian cancer.
von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. von Minckwitz G, et al. Among authors: bauknecht t. Ann Oncol. 1999 Jul;10(7):853-5. doi: 10.1023/a:1008364327684. Ann Oncol. 1999. PMID: 10470434 Free article. Clinical Trial.
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U. du BA, et al. Among authors: bauknecht t. Ann Oncol. 2002 Feb;13(2):251-7. doi: 10.1093/annonc/mdf038. Ann Oncol. 2002. PMID: 11886002 Free article. Clinical Trial.
Clinical phase I study with one-hour paclitaxel infusion.
Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H. Mross K, et al. Among authors: bauknecht t. Ann Oncol. 1998 May;9(5):569-72. doi: 10.1023/a:1008217429971. Ann Oncol. 1998. PMID: 9653500 Free article. Clinical Trial.
112 results